OPTIMIZING THE DIAGNOSIS OF NMOSD AND MOGAD IN N.

MACEDONIA
Teodora Brnjarchevska Blazhevska, Olgica Sibinovska, Tamara Savevska, Gorjan Milanovski, Meri Kirijas, Aleksandar
Petlichkovski
Institute for immunobiology and human genetics, St.Cyril and Methodius University of Skopje

Neuromyelitis optica spectrum disorder

(NMOSD) represents a rare, not yet fully
defined complex of phenotype
manifestations of an autoimmune
inflammatory disease of the CNS. The
optic nerve, spinal cord and brainstem
are most often impacted. Classically
considered a monophasic disease, it is
now recognized as a condition with
recurrent attacks, separated with
periods of remission. Besides the use for
diagnostic purpose, Aqp4 IgG testing has
also prognostic and therapeutic
implications. Some of the seronegative
patients have antibodies against myelin
oligodendrocyte protein (MOG IgG).
MOGAD-heterogeneous group of
diseases with different clinical features,
treatment and prognosis.

In our country there is 21 patient diagnosed with NMOSD. Only 5 of them are on treatment
with Satralizumab , as part of a compassionate use program. Our institute together with the
University Clinic of Neurology Skopje works on a project to include all of the patients
diagnosed with NMOSD in a program from the Ministry of health for biological therapy with
Satralizumab. One of the criteria for treatment with Satralizumab is seropositivity for Aqp4
IgG.

To date 338 patients with symptoms of

demyelinating disease have been
referred to our Institute . We were using
NMOSD IIFT panel detecting Aqp4+MOG
IgG from EUROIMMUN AG. The positivity
rate is 5,33 % for Aqp4 and 1.29% for
MOG.